Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
about
Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran.Cytomegalovirus and Aspergillus spp. coinfection in organ transplantation: a case report and review of the literatureCytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.A molecular assay for sensitive detection of pathogen-specific T-cellsMechanism of curcumin resistance to human cytomegalovirus in HELF cellsHuman cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency in vitroGeneration of a specific-pathogen-free baboon colony.The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturationHLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation.A peptide inhibitor of cytomegalovirus infection from human hemofiltrateEffects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantationNK cells and immune "memory"Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infectionAn optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft RejectionGeneration of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Outcomes in pediatric solid-organ transplantation.Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation.Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantationCytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies.The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation.Visceral leishmaniasis in hematopoietic stem cell transplantation.Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.
P2860
Q33624126-84F0C0CD-49FA-4DEC-9235-EEBC065DE4B3Q33628293-4CD9B25A-57F4-48BD-8352-C9D9D146D9B4Q33912913-E760E3FC-4CD3-4C44-80A7-846933D56C78Q33996692-1F2F9293-1D54-4060-871C-73BA71B14E94Q34045330-6E745B52-65AB-4B7C-9D03-04D8BCDF3B49Q34059073-64349F92-344F-4DDF-BF5C-4A97D123CE1BQ34362454-6631EC85-4BD2-4A9B-84E2-5CFF82C60159Q34400561-D21BF837-0D28-4CF7-B9D7-24C795ED74B3Q34506165-31CE3380-78C1-4714-B957-E7329D374362Q34821852-346D7B78-03C2-4813-A1FF-97A4D4F70F0FQ35134243-378B8F56-7E2E-43A3-9927-E90B76C4DA19Q35539280-CE9C52B9-968A-4007-AE6B-DB8A6E952D5DQ36023008-3FD6EF71-A626-41C3-AC52-0F29663C3194Q36300011-DA95F69A-25E4-4712-AB86-E0563F56FEBCQ36559969-341CC8A3-B59F-4B3E-8A91-F65D0257E794Q36901437-B7D824F5-8CD4-4F09-B932-3D5B35227B35Q37450543-839D1D7A-8E4B-4C87-9192-E46A2DC64450Q37839213-C29C62CF-CA0F-479C-AAA8-F088BB75A385Q39296120-49A6A1B9-B973-43E2-8051-595AC51AA380Q40537018-74844275-0D8A-48D8-BD3E-707ACECBDCC8Q40791125-87031AB9-1CA1-4BF4-BEBC-DE67067E70DBQ41947385-83937446-FE19-4CA3-A4F7-FC83B287E612Q42281180-3A209BD4-8355-467C-BCE8-54456737D797Q42366690-EC27B335-86C6-40DE-89B9-8FCF9A24233FQ43601622-6B45028E-A923-4349-A56C-6CE02E2C980FQ44087042-A528CF26-8566-4AE4-91BD-F48C5CF8366FQ48331811-6D5DE66D-D17D-48CB-A863-58B4B96A9A04Q52691329-BC8759CB-6A70-460C-8D17-AE79FC11D00B
P2860
Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytomegalovirus infection and ...... g solid organ transplantation.
@en
Cytomegalovirus infection and ...... g solid organ transplantation.
@nl
type
label
Cytomegalovirus infection and ...... g solid organ transplantation.
@en
Cytomegalovirus infection and ...... g solid organ transplantation.
@nl
prefLabel
Cytomegalovirus infection and ...... g solid organ transplantation.
@en
Cytomegalovirus infection and ...... g solid organ transplantation.
@nl
P921
P1476
Cytomegalovirus infection and ...... g solid organ transplantation.
@en
P2093
R A Fisher
P304
P356
10.1111/J.1399-3062.2009.00372.X
P577
2009-02-18T00:00:00Z